A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CAM / constitutively active mutant

[Related PubMed/MEDLINE]
Total Number of Papers: 37
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CAM  (>> Co-occurring Abbreviation)
Long Form:   constitutively active mutant
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant. GPCR, MD
2017 Structural heterogeneity of the mu-opioid receptor's conformational ensemble in the apo state. GPCRs, muOR
2017 The role of alpha1-adrenergic receptors in regulating metabolism: increased glucose tolerance, leptin secretion and lipid oxidation. alpha1-ARs, KO
2014 Long-term alpha1B-adrenergic receptor activation shortens lifespan, while alpha1A-adrenergic receptor stimulation prolongs lifespan in association with decreased cancer incidence. alpha1-AR, WT
2013 Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors. AgRP, MC4R
2013 alpha₁A-adrenergic receptors regulate cardiac hypertrophy in vivo through interleukin-6 secretion. ARs, IL-6, NF-kappaB
2013 High-level expression, purification and characterization of a constitutively active thromboxane A2 receptor polymorphic variant. CD, GPCRs
2012 alpha(1A)-adrenergic receptor differentially regulates STAT3 phosphorylation through PKCϵ and PKCdelta in myocytes. ARs, GPCRs
2011 Differential Virtual Screening (DVS) with Active and Inactive Molecular Models for Finding and Profiling GPCR Modulators: Case of the CCK1 Receptor. DVS, DVS, MD
10  2011 Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. WT
11  2010 Screening for novel constitutively active CXCR2 mutants and their cellular effects. CXCR2, GPCR
12  2010 Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism. Ang II, Bpa, MPA
13  2009 Activation switch in the transmembrane domain of metabotropic glutamate receptor. ECD, mGluRs, TMD
14  2009 Constitutively active mutant N111G of angiotensin II type 1 (AT(1)) receptor induces homologous internalization through mediation of AT(1)-receptor antagonist. IP, WT
15  2008 A new silent germline mutation of the TSH receptor: coexpression in a hyperthyroid family member with a second activating somatic mutation. cAMP, TSHR
16  2008 Constitutively active mutants of the histamine H1 receptor suggest a conserved hydrophobic asparagine-cage that constrains the activation of class A G protein-coupled receptors. GPCRs
17  2007 ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor. DPCPX, GPCRs
18  2006 The active and the inactive form of the hAT1 receptor have an identical ligand-binding environment: an MPA study on a constitutively active angiotensin II receptor mutant. AT1, GPCRs
19  2005 A "locked-on," constitutively active mutant of the adenosine A1 receptor. ---
20  2005 alpha1A- but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism. ARs
21  2005 Both alpha(1A)- and alpha(1B)-adrenergic receptors crosstalk to down regulate beta(1)-ARs in mouse heart: coupling to differential PTX-sensitive pathways. ARs
22  2005 Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors. Dmt-Tic, NTI, TIPP
23  2004 Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the beta2 adrenergic receptor. WT
24  2003 Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2. WT
25  2002 A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. SDF-1
26  2002 Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor. ---
27  2002 Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the beta(2)-adrenergic receptor. ---
28  2001 A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors. IP, WT
29  2001 Inverse agonist activity at the alpha(2A)-adrenergic receptor. GPCRs, WT
30  2000 Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. GRKs
31  1999 Visualizing differences in ligand regulation of wild-type and constitutively active mutant beta(2)-adrenoceptor-green fluorescent protein fusion proteins. GFP
32  1998 Efficacy of inverse agonists in cells overexpressing a constitutively active beta2-adrenoceptor and type II adenylyl cyclase. ---
33  1997 Functional consequences of constitutively active alpha2A-adrenergic receptor expression in 3T3F442A preadipocytes and adipocytes. AR
34  1997 Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists. PLD
35  1996 A constitutively active mutant of the alpha 1B-adrenergic receptor can cause greater agonist-dependent down-regulation of the G-proteins G9 alpha and G11 alpha than the wild-type receptor. ---
36  1996 Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. ---
37  1996 Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. ---